

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nicholas BARDEN et al.
Title: MEANS AND METHODS FOR
DIAGNOSING AND TREATING
AFFECTIVE DISORDERS
Appl. No.: 10/533,298
Filing Date: 10/14/2005
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

DEC 01 2005

Date _____

By _____

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5483
Facsimile: (202) 672-5399

Richard C. Peet
Attorney for Applicant
Registration No. 35,792

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: DEC 01 2005
 (use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/553,298
Filing Date	10/14/2005
First Named Inventor	Nicholas BARDEN
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	028622-0137

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	2004/0229262	A1	FRANCO et al.	11/18/2004	
	A2	6,214,581	B1	LYNCH et al.	04/10/2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A3	EP	1199372	A2	ASTRAZENECA AB	04/24/2002		
	A4	EP	1310493	A1	PFIZER PRODUCTS, INC.	05/14/2003	= A8	
	A5	WO	99/55901	A	ABBOTT LABORATORIES	11/04/1999		
	A6	WO	01/44213	A	ASTRAZENECA AB	06/21/2001		
	A7	WO	01/62787	A1	OXFORD GLYCOSCIENCES (UK) LIMITED	08/30/2001		
	A8	WO	03/42190	A	PFIZER PRODUCTS INC.	05/22/2003	= A4	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A9	BURNSTOCK, Geoffrey, "Introduction: P2 Receptors," Current Topics in Medicinal Chemistry, Vol. 4, 2004, pp. 793-803.	
	A10	HUMPHREYS et al., "Isoquinolines as Antagonists of the P2X ₇ Nucleotide Receptor: High Selectivity for the Human versus Rat Receptor Homologues," Molecular Pharmacology, Vol. 54, 1998, pp. 22-32.	
	A11	LIU et al., "Technological Advances in High-Throughput Screening," Am. J. Pharmacogenomics, Vol. 4, No. 4, 2004, pp. 263-276.	
	A12	MUZYNY et al., "Homo sapiens 12 BAC RP 11-946P6 (Roswell Park Cancer Institute BAC Library) complete sequence," December 2, 2002, XP002284283 (Database EMBL, 5/14/1999; Database Accession No. AC007546).	
	A13	NORTH et al., "Pharmacology of clones P2X receptors," Annual Review of Pharmacology and Toxicology, Vol. 40, 2000, pp. 563-580.	
	A14	SANZ et al., "Tenidap enhances P2Z/P2X ₇ receptor signaling in macrophages," European Journal of Pharmacology, Vol. 355, 1998, pp. 235-244.	
	A15	SILVERMAN, Richard B., The Organic Chemistry of Drug Design and Drug Action, Second Edition, Elsevier Academic Press, Chapter 2, pp. 7-120.	
	A16	WILLIAMS, Michael, "Purinergic Drugs: Opportunities in the 1990s," Drug Development Research, Vol. 28, 1993, pp. 438-444.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.